International Scientific Advisory Board

The main responsibilities of the International Scientific Advisory Committee Board (IASB) are to provide advice, support and guidance to the CKB Steering Committee and Principal Investigators on CKB’s scientific direction, strategy and operations, and the furtherance of its scientific mission. This includes:

  • advice on the long-term strategic development of the Project
  • advice on specific research projects to be undertaken and their priorities
  • advice and support on fund-raising activities related to the Project
  • advice and information on development of new technologies that may be relevant to the Project (eg, genetic sequencing)
  • advice and information on legal, clinical and policy issues related to the Project
  • advice from a scientific perspective on issues related to collaborative research involving CKB, including access to data and materials and data release
  • assessment of CKB’s scientific outputs and its contribution to the scientific community and any health related outcomes.

The ISAB generally meets once a year unless, in exceptional circumstances, additional meetings are considered necessary by the CKB Steering Committee or ISAB members.

The CKB Steering Committee is jointly responsible for selecting, appointing, removing and replacing all Members, including two Co-Chairs. ISAB comprises approximately 10-12 Members who generally serve for three years; appointments are renewable at the discretion of the CKB Steering Committee for a further three years.

Current membership includes:

-    David Hunter, Nuffield Department of University of Oxford (Co-Chair)

-    Qiming Zhan, Peking University Health Science Center ( Co-Chair)

-    John Danesh, Cardiovascular Epidemiology Unit, University of Cambridge

-    George Davey-Smith, MRC Integrative Epidemiology Unit, University of Bristol

-    Fu Gao, Chinese Center for Disease Control and Prevention

-    Frank Hu, Harvard School of Public Health

-    Michael Gaziano, Million Veterans Programme and Harvard Medical School.

-    Gil McVean, Big Data Institute, University of Oxford.

-    Chen Wang, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC)

-    Tim Waterboer, German Cancer Research Centre - DKFZ

-    Xu Xun, BGI Research